On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an anti-CTLA-4 antibody and candidate for the treatment of advanced solid tumours.
Soft Close, Hard Lessons: Full Court Reinforces Purposive Construction of Patent Claims and the Disclosure Requirements for Divisional Patents
Glass Hardware Australia Pty Ltd v TCT Group Pty Ltd [2024] FCAFC 95 Date of decision: 17 July 2024 Body: Full Court of the Federal Court of...